Breyanzi vs Yescarta: Side-by-Side Comparison
Quick answer: Breyanzi and Yescarta are both cd19-directed car-t cell therapy used for similar indications. They share a mechanism of action but differ in dosing, half-life, side-effect profile, and clinical preferences. Switching between them is a clinical decision.
Side-by-side comparison
| Feature | Breyanzi | Yescarta |
|---|---|---|
| Drug class | CD19-directed CAR-T cell therapy | CD19-directed CAR-T cell therapy |
| ATC code | L01XL04 | L01XL |
| Primary indications | Relapsed/refractory large B-cell lymphoma, Chronic lymphocytic leukemia | Relapsed/refractory large B-cell lymphoma, Follicular lymphoma |
| Mechanism | Brand name for lisocabtagene maraleucel; autologous CD19-directed chimeric antigen receptor T-cell immunotherapy | Autologous CD19-targeted chimeric antigen receptor T cells that lyse CD19-expressing B cells |
| Common dose | Single IV infusion of 90-110 × 10^6 CAR-positive T cells | Single IV infusion of 2 x 10^6 CAR-positive T cells/kg |
| Detail page | Breyanzi details → | Yescarta details → |
How to choose between Breyanzi and Yescarta
Both medicines belong to the same therapeutic class and address overlapping indications. Selection between them depends on:
- Patient-specific factors: age, kidney and liver function, other medications, allergies, comorbidities
- Specific clinical indication: some class members are preferred for particular conditions or guideline recommendations
- Dosing preference: once-daily vs twice-daily, oral vs injectable, food requirements
- Tolerability: individual side-effect profiles vary even within a class
- Drug interactions: patient's other medications may interact differently with each option
- Cost and availability: generic availability, insurance coverage, regional access
Should you switch?
Switching between class members is a clinical decision, not a self-help one. Reasons your prescriber may consider switching include:
- Inadequate response to current medication
- Side effects affecting quality of life
- New drug interactions due to a recently added medication
- Cost or availability changes
- Updated guidelines favoring a different option
Never switch medications, change dose, or stop without consulting your prescriber.
Related
All CD19-directed CAR-T cell therapy on iMedic · Breyanzi full details · Yescarta full details
Frequently asked questions
Is Breyanzi better than Yescarta?
Neither is universally 'better.' They are both cd19-directed car-t cell therapy with similar mechanisms of action. The right choice depends on the specific clinical situation, patient factors, dosing preferences, drug interactions, and tolerability. Discuss with your prescriber.
Can I switch from Breyanzi to Yescarta?
Switching is possible but should be done under clinical supervision. Different class members may not be interchangeable on a 1:1 dose basis, and tapering or transition strategies vary. Never switch on your own.
Do Breyanzi and Yescarta have the same side effects?
They share class-wide side-effect tendencies but differ in individual profiles. Some patients tolerate one better than the other. Specific frequency and severity of side effects can be found on each medicine's individual page.
Are Breyanzi and Yescarta available as generics?
Generic availability depends on patent status in your country. Most well-established class members are available generically and are clinically equivalent to brand-name versions.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.